BIOASSAY TESTS - THYROID COUNTS UPDATED: MARCH 2017

According to DHS 157.22(4) and WISREG-1556 Vol. 9, Rev. 2 for purposes of assessing dose used to determine compliance with occupational dose equivalent limits, a licensee or registrant shall take suitable and timely measurements of all of quantities of radionuclides in the body.

Preparation

Any radiopharmacist or radiopharmacy technician who routinely prepares I-131 will perform a bioassay at weekly intervals.

Any radiopharmacy observer will perform a bioassay as described below under I-131 Solution.

Administration

I-131 Capsule

Any Nuclear Medicine staff physician, resident, technologist, or student (and any other personnel involved) who are in the room for the administration(s) of I-131 capsules that total more than 100 mCi in one work day will perform a bioassay not before 6 hours following administration and no longer than 72 hours.

I-131 Solution

Any Nuclear Medicine staff physician, resident, technologist, or student (and any other personnel involved) who administer any I-131 solution will perform a bioassay not before 6 hours following administration and no longer than 72 hours. (This also includes radiopharmacy observers.)

The Capintec system will convert the activity in the thyroid to μ Ci using the calculated efficiency (efficiency is calculated with a Ba-133 source).

Evaluation Limit: 0.1 uCi Any thyroid bioassay results greater than 0.1 μ Ci shall be reported to both individuals listed below within the next working day

Investigational Limit: 0.5 uCi Any thyroid bioassay results greater than 0.5 uCl shall be reported to both individuals listed below immediately

Derek Fuerbringer		Jason Timm
Radiology Technical Manager	AND	Radiation Safety Officer
dfuerbringer@uwhealth.org		Jason.timm@wisc.edu
(608) 263-0625		(608) 890-2039

Include your name, μ Ci, expected date of contamination/uptake and possible explanation. All bioassay information with be stored on the Capintec system and then archived on compact disc.

References

NUREG/CR-4884 pg. B-103 NRC Reg Guide 8.9 "Acceptable Concepts, Models, Equations, and Assumptions for a Bioassay Program"

Reviewed By:

Scott B. Perlman, MD, MS Chief, Nuclear Medicine Jason Timm Radiation Safety Officer John Vetter, PhD, DABR Medical Physicist

Derek Fuerbringer, CNMT Manager, Nuclear Medicine Scott Knishka, RPh, BCNP Radiopharmacist